Study drug administration
| . | Cohort 1, 20 mg/m2 (n = 59) . | Cohort 2, 20/27 mg/m2 (n = 70) . | Total (N = 129) . |
|---|---|---|---|
| No. of cycles started, n (%) | |||
| Median (range) | 7.0 (1-21) | 6.5 (1-13) | 7.0 (1-21) |
| 1-3 | 17 (28.8) | 21 (30.0) | 38 (29.5) |
| 4-6 | 12 (20.3) | 14 (20.0) | 26 (20.2) |
| 7-9 | 7 (11.9) | 4 (5.7) | 11 (8.5) |
| ≥ 10 | 23 (39.0) | 31 (44.3) | 54 (41.9) |
| Completed 12 cycles, n (%) | 17 (28.8) | 29 (41.4) | 46 (35.7) |
| Mean dose, mg/m2 | |||
| Mean (SD) | 20.4 (1.9) | 24.5 (2.4) | 22.6 (3.0) |
| Median (range) | 20.0 (16.0-25.2) | 25.7 (17.3-26.6) | 22.5 (16.0-26.6) |
| Relative dose intensity, % | |||
| Median (range) | 91.8 (36.5-100.0) | 95.1 (50.0-100.0) | 94.0 (36.5-100.0) |
| . | Cohort 1, 20 mg/m2 (n = 59) . | Cohort 2, 20/27 mg/m2 (n = 70) . | Total (N = 129) . |
|---|---|---|---|
| No. of cycles started, n (%) | |||
| Median (range) | 7.0 (1-21) | 6.5 (1-13) | 7.0 (1-21) |
| 1-3 | 17 (28.8) | 21 (30.0) | 38 (29.5) |
| 4-6 | 12 (20.3) | 14 (20.0) | 26 (20.2) |
| 7-9 | 7 (11.9) | 4 (5.7) | 11 (8.5) |
| ≥ 10 | 23 (39.0) | 31 (44.3) | 54 (41.9) |
| Completed 12 cycles, n (%) | 17 (28.8) | 29 (41.4) | 46 (35.7) |
| Mean dose, mg/m2 | |||
| Mean (SD) | 20.4 (1.9) | 24.5 (2.4) | 22.6 (3.0) |
| Median (range) | 20.0 (16.0-25.2) | 25.7 (17.3-26.6) | 22.5 (16.0-26.6) |
| Relative dose intensity, % | |||
| Median (range) | 91.8 (36.5-100.0) | 95.1 (50.0-100.0) | 94.0 (36.5-100.0) |